A long-term follow-up of the chimeric antigen receptor T-cell treatment, axicabtagene ciloleucel (Axi-cel) in patients with B-cell lymphoma, presented at the 2018 American Society of Clinical Oncology Annual Meeting, found that a response at 3 months may be prognostic for long-term remission in those patients.
A long-term follow-up of the chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (Axi-cel) in patients with B-cell lymphoma, presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, found that a response at 3 months may be prognostic for long-term remission in those patients.
An autologous anti-CD19 CAR T-cell therapy developed by Kite Pharma, Axi-cel was granted priority review following interim results that showed 82% of patients had met the primary endpoint of an objective response rate at 8.4 months of follow-up. Subsequently, the drug was approved within 5 months by the FDA for the treatment of adult patients with relapsed/refractory large B-cell lymphoma whose disease has progressed on at least 2 lines of systemic therapy.
At ASCO, Frederick Locke, MD, program coleader, Immunology, Moffitt Cancer Center and Research Institute, presented the longer-term update during an afternoon session.1
Patients (n = 101) with refractory large B-cell lymphoma received 2 × 106 CAR T cells/kg after after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine.2 The best objective response rates (ORRs) were analyzed by both the local investigators and by an independent review committee (IRC).
Results collected at a median follow-up of 15.4 months showed that while the best ORR was 82% at primary analysis (median follow-up of 8.7 months), it remained consistent with a more long-term follow-up by local doctors (median 15.4 months). The complete response (CR) rates increased from 54% to 58%. Of the 34 patients who had a partial response (PR) at 3 months, 18 (44%) converted to a CR by the long-term follow-up cut off.
The researchers report observing a high concordance (77% to 79%) for ORRs between local investigators and the IRC at all times assessed.
Locke emphasized that patients who responded at 3 months had an 80% likelihood of a durable response at 12 months. Analysis of progression-free survival (PFS) by local investigators found that most of the 60 patients with disease control (stable disease or better) at 3 months had prolonged disease control and similar PFS rates over the duration:
The adverse events, primarily cytokine release syndrome (CRS) and neurologic events, were observed at a similar rate across all response groups, Locke said. CRS was observed in all 9 patients with PR, but all were low grade (<3); 39 CR patients experienced CRS, of which 5 were grade 3 or higher. In total, 7 PR patients experienced neurologic events, 3 of whom had grade 3 or higher events; of the 28 CR patients who had neurologic adverse events, 15 were grade 3 or higher.
The authors concluded that based on the ORR and increasing CR rates during the long-term follow-up, patients can achieve CR even 1-year out following infusion of the Axi-cel CAR T-cell treatment, which suggests that responses deepen over time.
“Patients who are in response at 3 months are 80% likely to maintain their response to the treatment at 12 months,” Locke said. He emphasized that a PR or CR at 3 months following the infusion can serve as a prognostic marker for long-term remission in patients with B-cell lymphoma administered Axi-cel.
Reference
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More